Leukemia & lymphoma · 2025
Early assessment of treatment response in AML using FLT PET/cT: a trial of the ECOG-ACRIN Cancer Research Group (EAI141).
Клиническое исследованиеСтатьяМногоцентровое исследованиеНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Jeraj Robert, Duan Fenghai, Mattison Ryan J, Romanoff Justin, Kostakoglu Lale, Arber Daniel A, Paietta Elisabeth M, Holter-Chakrabarty Jennifer L, Arnold Charles D, Strickland Stephen A, Whisenant Jennifer G, Siegel Barry A, Uy Geoffrey L, Begna Kebede H, Wiseman Gregory A, Hall Aric C, Perlman Scott B, Litzow Mark R, Mankoff David A
Аннотация
EAI141 was a prospective, multi-center trial designed to assess 3'-deoxy-3'-18F-fluorothymidine (FLT) PET/CT as a treatment response biomarker. The primary objective was to evaluate the negative predictive value (NPV) of post-treatment 'day 14' FLT-uptake (clinically non-responding patients with high FLT uptake). Among 87 patients enrolled from 9 centers, 61 were evaluable for the primary endpoint. The NPV for FLT PET/CT was 0.20 (3/15, 95% CI 0.04-0.48) compared to the NPV for nadir bone marrow of 0.25 (4/16, 95% CI 0.07-0.52). This first multi-center molecular imaging study in patients with AML demonstrated the feasibility of FLT PET/CT imaging. While molecular imaging did not predict response status more accurately than the nadir marrow, this study showed limitations in the accuracy of the 'day 14' marrow as a predictor of response and suggested added benefit by combining a marrow assessment and molecular imaging at an earlier time point.